Cortisol-induced SRSF3 expression promotes GR splicing, RACK1 expression and breast cancer cells migration

Buoso, Erica; Ronfani, Melania; Galasso, Marilisa; Ventura, Denise; Corsini, Emanuela; Racchi, Marco

doi:10.1016/j.phrs.2019.03.008

Cited by 28 publications

(33 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TNBC is a sub-type of breast cancer with ER-deficiency, HER2-decificiency, and PR-deficiency features 39,40 . Although the molecular targeting agents have been applied, the clinical outcomes and the prognosis of patients with TNBC are still poor 41,42 .…”

Section: Discussionmentioning

confidence: 99%

FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis

Yang

Ren²,

Wang³

et al. 2020

Cell Death Dis

View full text Add to dashboard Cite

The factor that binds to the inducer of short transcripts‐1 (FBI-1) is a transcription suppressor and an important proto‐oncogene that plays multiple roles in carcinogenesis and therapeutic resistance. In the present work, our results indicated that FBI-1 enhanced the resistance of triple-negative breast cancer (TNBC) cells to chemotherapeutic agents by repressing the expression of micoRNA-30c targeting the pregnane X receptor (PXR). The expression of FBI-1 was positively related to PXR and its downstream drug resistance-related genes in TNBC tissues. FBI-1 enhanced the expression of PXR and enhanced the activation of the PXR pathway. The miR-30c decreased the expression of PXR by targeting the 3′-UTR of PXR, and FBI-1 increased the expression of PXR by repressing miR-30c’s expression. Through the miR-30c/PXR axis, FBI-1 accelerated the clearance or elimination of antitumor agents in TNBC cells (the TNBC cell lines or the patients derived cells [PDCs]) and induced the resistance of cells to antitumor agents. Therefore, the results indicated that the miR-30c/PXR axis participates in the FBI-1-mediated drug-resistance of TNBC cells.

show abstract

Section: Discussionmentioning

confidence: 99%

FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis

Yang

Ren²,

Wang³

et al. 2020

Cell Death Dis

View full text Add to dashboard Cite

show abstract

“…It was shown that using 12 such isoforms as biomarkers can distinguish a breast cancer tumor from normal tissue and moreover specify the grade level of the tumor [32]. Many splicing factors have been shown to have a role in breast cancer and to promote its progression, including SRSF1 [30,47,48], SRSF3 [49], SRSF5 [50], SRSF6 [40][41][42], SRSF10 [51], HNRNPA1 [33], HNRNPA2B1 [34,35,52], HNRNPM [53], HNRNPK [36,37], HNRNPL [54], RBFOX2 [55], ESRP1/2 [55], PTBP1 [38,39] RBM5/10 [56], Sam68 [57] and FOX2 [58]. Since our sequencing of saliva RNA identified 28 splicing factors out of the known 71, we focused on this group as a possible marker.…”

Section: Discussionmentioning

confidence: 99%

Splicing Factor Transcript Abundance in Saliva as a Diagnostic Tool for Breast Cancer

Bentata

Morgenstern

Nevo

et al. 2020

Genes

View full text Add to dashboard Cite

Breast cancer is the second leading cause of death in women above 60 years in the US. Screening mammography is recommended for women above 50 years; however, 22% of breast cancer cases are diagnosed in women below this age. We set out to develop a test based on the detection of cell-free RNA from saliva. To this end, we sequenced RNA from a pool of ten women. The 1254 transcripts identified were enriched for genes with an annotation of alternative pre-mRNA splicing. Pre-mRNA splicing is a tightly regulated process and its misregulation in cancer cells promotes the formation of cancer-driving isoforms. For these reasons, we chose to focus on splicing factors as biomarkers for the early detection of breast cancer. We found that the level of the splicing factors is unique to each woman and consistent in the same woman at different time points. Next, we extracted RNA from 36 healthy subjects and 31 breast cancer patients. Recording the mRNA level of seven splicing factors in these samples demonstrated that the combination of all these factors is different in the two groups (p value = 0.005). Our results demonstrate a differential abundance of splicing factor mRNA in the saliva of breast cancer patients.

show abstract

“…Nowadays, RACK1 is known to be involved not only in the immune response but also acts as a signalling hub, facilitating the cross-talk between several pathways involved in various biological events such as neuronal activity [242,243] and cancer progression [19]. Indeed, RACK1 is aberrantly expressed in several cancer types [244], including BC [21,245]. In this regard, RACK1 has been suggested as a possible BC biomarker [246,247] since it has been directly correlated with increased proliferation rate, migration and invasion of BC cells both in vitro and in vivo [248][249][250] and emerged as superior predictor of BC prognosis [250].…”

Section: Rack1 As a Possible Target Of Edcsmentioning

confidence: 99%

Endocrine-Disrupting Chemicals’ (EDCs) Effects on Tumour Microenvironment and Cancer Progression: Emerging Contribution of RACK1

Buoso

Masi

Racchi

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

Endocrine disruptors (EDCs) can display estrogenic and androgenic effects, and their exposure has been linked to increased cancer risk. EDCs have been shown to directly affect cancer cell regulation and progression, but their influence on tumour microenvironment is still not completely elucidated. In this context, the signalling hub protein RACK1 (Receptor for Activated C Kinase 1) could represent a nexus between cancer and the immune system due to its roles in cancer progression and innate immune activation. Since RACK1 is a relevant EDCs target that responds to steroid-active compounds, it could be considered a molecular bridge between the endocrine-regulated tumour microenvironment and the innate immune system. We provide an analysis of immunomodulatory and cancer-promoting effects of different EDCs in shaping tumour microenvironment, with a final focus on the scaffold protein RACK1 as a pivotal molecular player due to its dual role in immune and cancer contexts.

show abstract

Cortisol-induced SRSF3 expression promotes GR splicing, RACK1 expression and breast cancer cells migration

Cited by 28 publications

References 55 publications

FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis

FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis

Splicing Factor Transcript Abundance in Saliva as a Diagnostic Tool for Breast Cancer

Endocrine-Disrupting Chemicals’ (EDCs) Effects on Tumour Microenvironment and Cancer Progression: Emerging Contribution of RACK1

Contact Info

Product

Resources

About